RECOVER Clinical Study Shows Meaningful Benefits of LivaNova’s VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression

LIVN 12.18.2024

Full Press ReleaseSEC FilingsOur LIVN Tweets

About Gravity Analytica

Recent News

  • 02.25.2025 - 4Q 2024 LivaNova PLC Earnings Conference Call
  • 01.21.2025 - LivaNova to Announce Fourth-Quarter and Full-Year 2024 Results
  • 01.06.2025 - LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer

Recent Filings

  • 01.17.2025 - 3 Initial statement of beneficial ownership of securities
  • 12.17.2024 - 4 Statement of changes in beneficial ownership of securities
  • 12.11.2024 - 144 Report of proposed sale of securities
PDF Version176.6 KB

Results published in two articles in Brain Stimulation

LONDON--(BUSINESS WIRE)--Dec. 18, 2024--LivaNova PLC(Nasdaq: LIVN), a market-leading medical technology company, today announced that the journalBrain Stimulationhas published two pivotal articles chronicling the unipolar cohort data set for theRECOVER clinical study. The researchers evaluated the safety and efficacy of LivaNova’s VNS TherapyTM System and its effectiveness on quality of life and daily function in this population of patients with treatment-resistant unipolar depression. Overall, the articles concluded that active VNS Therapy, as compared with a no-stimulation control (or sham VNS Therapy), safely and effectively demonstrated clinically meaningful therapeutic effects on depressive symptoms and positive effects on quality of life and daily function. These findings support the use of VNS Therapy to deliver vagus nerve stimulation (VNS) in treatment-resistant depression (TRD) patients.

A total of 493 adults with at least four documented unsuccessful attempts with antidepressant treatments participated in the unipolar cohort of the RECOVER study. At baseline, unipolar patients in the study failed more than 13 antidepressant treatments (on average) – this included, for the majority, one or more interventional therapies (e.g., transcranial magnetic stimulation, electroconvulsive therapy, or esketamine). While the RECOVER study did not meet the primary endpoint due to a strong and unforeseen response in the sham group, the active treatment arm demonstrated statistically significant and clinically meaningful improvement from the treatment arm’s baseline. Further, the RECOVER study demonstrated statistically significant and clinically meaningful benefits in select secondary endpoints for this cohort. Based upon these findings and the positive effects for thosewhoreceived VNS Therapy, the Company conducted additional in-depth data analyses and plans to submit three additional critical manuscripts to report on the outcomes.

“Participants in the trial had severe, refractory depression that could not be treated effectively with other FDA-approved treatments, and most have had large portions of their lives profoundly negatively impacted by depression,” saidCharles Conway, MD, director of the Washington University Resistant Mood Disorders Center atWashington University School of MedicineinSt. Louis. Conway is the study's lead investigator and first author of the mood outcomes article. “For this sample of markedly ill TRD participants, I am encouraged by the findings, which revealed that active VNS performed better than sham VNS treatment in all measures, and that active VNS demonstrated clinically meaningful, safe therapeutic effects. Multiple clinician, patient, and independent observer ratings separated between the active and sham unipolar arms.”

The first article, “Vagus Nerve Stimulation in Treatment-Resistant Depression: A One-Year, Randomized, Sham-Controlled Trial,”1outlines the safety and effectiveness of adjunctive VNS Therapy in treating patients with unipolar TRD. The primary endpoint measured the difference in the percentage of time in antidepressant response between active VNS Therapy and sham VNS Therapy, with response defined as at least a 50% reduction from baseline using theMontgomery-Åsberg Depression Rating Scale (MADRS) total score. While the predetermined p-value was p<0.023, the observed mean percentage of time in response was p=0.137.

Analyses of secondary endpoints revealed antidepressant benefits significantly favoring active VNS Therapy as opposed to sham VNS Therapy as measured by ratings from on-site clinicians (Clinical Global Impression-Improvement, or CGI-I), patients themselves (Quick Inventory of Depressive Symptomology–Self Report, or QIDS-SR), and offsite masked raters (Quick Inventory of Depressive Symptomology–Clinical, or QIDS-C).

Results included:

  • Participants with active VNS Therapy had significantly more percentage of time in response with CGI-I (P=0.004) and QIDS-SR (P=0.049) compared with sham VNS Therapy.
  • For percentage of time in partial response, active VNS Therapy showed significant benefit with QIDS-C (P=0.006) and CGI-I (P<0.001) compared with sham VNS Therapy. Partial response is defined as improvement of ≥30% from baseline for QIDS-C or a score of ≤3 for CGI-I.
  • No differences between treatment groups were observed in suicidal ideation and intent as measured by the S-STS2items 6 and 8 (P=0.239).

“The composite of the mood findings, especially in the partial response rates on multiple ratings scales, along with the low rate of adverse events, support that this device demonstrated safe antidepressant efficacy for these patients,” said Conway.

The second article, “Effects of Vagus Nerve Stimulation on Daily Function and Quality of Life in Markedly Treatment-Resistant Major Depression: Findings from a One-Year, Randomized, Sham-Controlled Trial,”3assesses VNS Therapy’s ability to improve quality of life (QoL) and daily function in patients with unipolar TRD. The results of this analysis demonstrated that adjunctive VNS Therapy provided greater improvements in QoL and daily function in patients with unipolar TRD when compared with sham VNS Therapy.

Results included:

  • The active VNS Therapy group showed greater improvements over the sham control group as measured by the mean change in scores from baseline in the Mini-Q-LES-Q4(P=0.050) and WPAI5item 6 (health condition’s effect on regular activities;P=0.050) used as continuous variables.
  • Time spent in a state of clinically meaningful benefit was significantly greater with active VNS Therapy compared to sham VNS Therapy, using the Q-LES-Q6(P=0.029), Mini-Q-LES-Q (P=0.011) and WPAI item 6 (P=0.039).
  • No differences between treatment groups were observed in the mean change in score from baseline with the WHODAS72.0 (P=0.304) and the EQ-5D8visual analog scale (P=0.125).

“Adjunctive VNS Therapy improves quality of life and psychosocial function in patients with major depressionwhohave not benefited from multiple antidepressant treatments,” saidA. John Rush, MD, Professor Emeritus atDuke-National UniversityofSingapore Medical Schooland lead author on this article. “For these patientswhoare profoundly impaired, largely unemployed, and markedly treatment-resistant, depressive symptoms alone are an incomplete gauge of the clinical impact of treatments. Symptoms, function, and quality of life taken together present a more complete picture of treatment effectiveness.”

These two articles published inBrain Stimulationare the first in a series that will detail the RECOVER unipolar cohort data.Three subsequent, supportive manuscriptswill feature outcomes from in-depth data analyses on select secondary endpoints. The totality of data presented in these five complementary articles will serve as the basis for LivaNova’s formal request to theU.S. Centers for Medicare and Medicaid Services(CMS) for VNS Therapy coverage.

“Patients in the RECOVER study are some of the most critically ill among those with treatment-resistant depression and they need more treatment options when existing therapies fail,” said Vladimir Makatsaria, Chief Executive Officer ofLivaNova. “The data from the RECOVER study and predecessor studies has shown that VNS Therapy is a safe and effective treatment option for these patients, providing hope for patients and families in similar situationswhohave few viable options. We look forward to sharing more of the important outcomes from the unipolar cohort with the intent to offer VNS Therapy as an important adjunctive treatment for these patients.”

RECOVER launched in 2019 as part of a Coverage withEvidence Developmentframework per the CMS National Coverage Determination process. For the unipolar cohort of RECOVER, enrollment was completed inMarch 2023, and the 12-month follow-up for those patients was completed inMarch 2024. No new safety issues were identified in the study.

About RECOVER

LivaNova’s VNS TherapyTM System has been approved for the treatment of depression since earning CE Mark in 2001 and 510(k) from theU.S. Food and Drug Administrationin 2005. RECOVER stands for A Prospective, Multi-center, RandomizedControlled Blinded Trial Demonstrating the Safety and Effectiveness ofVNS Therapy System as AdjunctiveTherapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression.

The largest randomized clinical study of its kind, RECOVER is examining up to 1,000 patients ages 18 or olderwhohave unipolar or bipolar depression that is difficult to treat. The double-blind, randomized controlled study is assessing how VNS Therapy can offer patients relief from their depressive symptoms and improve quality of life. It is being carried out at up to 100 leading hospitals and medical centers acrossthe United States.

About VNS Therapy for Depression

The VNS TherapyTM System, SymmetryTM, isU.S. Food and Drug Administration-approved and indicated in theU.S.for the adjunctive long-term treatment of chronic or recurrent depression for patients 18 years of age or olderwhoare experiencing a major depressive episode and have not had an adequate response to four or more adequate antidepressant treatments The most commonly reported side effects are voice alteration or hoarseness, prickling or tingling in the skin, increased coughing, shortness of breath, and sore throat. Infection is the most common complication of the surgical procedure. Important safety information is available atwww.livanova.com/depression/en-us/safety-information.

References

  1. Conway CR, et al. Vagus nerve stimulation in treatment-resistant depression: A one-year, randomized, sham-controlled trial. Brain Stimulation.Dec. 18, 2024. DOI: 10.1016/j.brs.2024.12.1191.
  2. The Sheehan Suicidality Tracking Scale (S-STS) is a clinician-administered rating scale that tracks treatment-emergent suicidal ideation and behaviors.
  3. Rush AJ, et al. Effects of vagus nerve stimulation on daily function and quality of life in markedly treatment-resistant major depression: Findings from a one-year, randomized, sham-controlled trial. Brain Stimulation.Dec. 18, 2024. DOI: 10.1016/j.brs.2024.12.1187.
  4. Mini-Q-LES-Q (Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form) is a quality-of-life measure from a self-report assessing the patient’s degree of enjoyment and satisfaction across seven domains as a subset of the Q-LES-Q.
  5. WPAI item 6 is a function measure from the Work Productivity and Activity Impairment (WPAI) Questionnaire.
  6. Q-LES-Q is a quality-of-life measure from a self-report assessing the patient’s degree of enjoyment and satisfaction experienced over the previous seven days across 14 domains.
  7. WHODAS (World Health Organization Disability Assessment Schedule) assesses the patient’s ability to perform activities in the previous month in six domains.
  8. The EuroQoL Five-Dimension Questionnaire (EQ-5D) is a generic QoL measure that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.

AboutLivaNova

LivaNova PLCis a global medical technology company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through medical technologies, delivering life-changing solutions in select neurological and cardiac conditions. Headquartered inLondon,LivaNovaemploys approximately 2,900 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals, and healthcare systems worldwide. For more information, please visitwww.livanova.com.

Safe Harbor Statement

This news release contains “forward-looking statements” concerning the Company’s goals, beliefs, expectations, strategies, objectives, plans, underlying assumptions, and other statements that are not necessarily based on historical facts. These statements include, but are not limited to, statements regarding the RECOVER study and the VNS TherapyTM System, SymmetryTM. Actual events may differ materially from those indicated in our forward-looking statements as a result of various factors, including those factors set forth in Item 1A of the Company’s most recent Annual Report on Form 10-K, as supplemented by any risk factors contained in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K.LivaNovaundertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241217812430/en/

LivaNova Investor Relations and Media Contacts+1 281-895-2382Briana GotlinVP, Investor RelationsInvestorRelations@livanova.comDeanna WilkeVP, Corporate CommunicationsCorporate.Communications@livanova.com

Source:LivaNova PLC

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com